Team 2019-10-09T19:16:00+00:00
Fred FrankFrederick Frank is Chairman of EVOLUTION Life Sciences Partners (ELSP). He is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm. Before joining ELSP, Mr. Frank was Chairman of Burrill Securities and Vice Chairman of Burrill & Company. He began his investment banking career at Smith, Barney & Co. in 1958, where he attained the positions of Co-Head of Research, Vice President, and Director. In 1969, he joined Lehman Brothers as a partner and eventually became Vice Chairman. At Lehman Brothers, Frank provided investment banking services to numerous companies in the pharmaceutical, biotechnology, healthcare services, medical device, and nutraceutical industries, and was involved in hundreds of financings, strategic alliances, and merger and acquisition transactions in the global healthcare industry. Mr. Frank was also Vice Chairman at both Barclays Capital and Peter J. Solomon Company.

Mr. Frank’s clients included Marion Laboratories, from leading the company’s initial public offering to its acquisition of the pharmaceutical division of Dow Chemical, creating Marion Merrill Dow. Together with Mary Tanner, Frank represented Marion Merrill Dow in its merger with Hoechst to form Hoechst Marion Roussel. Frank also represented Synthélabo in France in its acquisition by Sanofi, and Genentech, commencing in 1995, with the purchase of a controlling interest by Roche and in its 1999 extension & modification. He advised CV Therapeutics in its $l.4 billion sale to Gilead Sciences; BioDuro, a Chinabased company, in its sale to PPD; TargeGen, in its sale to Sanofi-Aventis, CGI Pharmaceuticals, in its sale to Gilead Sciences; and OSI Pharmaceuticals in its sale to Astellas Pharma.

Mr. Frank is a Senior Advisor to PureTech Ventures; Director at Landec Corporation and a former Director and current Advisor to the Board of PDL BioPharma; a Director Emeritus at the Institute For Systems Biology, a member of the board of the Life Sciences Foundation; a past Director of the Salk Institute; a member of the Yale School of Organization and Management Advisory Board, Chairman, a member of the Pharmaceutical Executive Magazine advisory board and The Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a member of the Advisory Board of The Harvard School of Public Health and also a past member of the Advisory Board of the Johns Hopkins’ Bloomberg School of Public Health, and he served on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He is past President of the Board of the The Hotchkiss School, and currently serves as a Trustee Emeritus. Frank received an M.B.A. from Stanford University and a B.A. from Yale University. He is also a chartered financial analyst.

Mr. Frank was honored for Outstanding Contributions in the Field of Immunology in 1998 by the Irvington Institute for Immunological Research, and, in 1997, he received the Biotech Meeting at Laguna Niguel Hall of Fame Award for Special Recognition for an Individual. He received The Albert Einstein Award from the Weizmann Institute of Science in 2004, the 2006 Gilda’s Club of New York City Visionary Award and was selected The Top 100 Living Contributors to Biotechnology by Reed Elsevier and in 2007 he received the Award for Excellence from the American Liver Foundation.

Tel: 212-461-1602

Mary Tanner is Senior Managing Director of EVOLUTION Life Sciences Partners (ELSP). She is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm. At Life Sciences Partners, Tanner specialized in healthcare investment and strategic advisory work. Before joining ELSP, Mary Tanner was Senior Managing Director of both Burrill & Company and Burrill Securities. She is a former Senior Managing Director at Lehman Brothers, Bear Stearns and Peter. J. Solomon Company.

At Lehman Brothers, with Frederick Frank, she headed a global healthcare investment banking franchise for over twenty years. Tanner has devoted more than 25 years to the global healthcare and biotechnology industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicines, as well as green technologies in chemicals.

In addition to her well known work with large companies, she specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments and cross-border mergers. Tanner has directed over 500 mergers and acquisitions, over 130 initial public offerings and hundreds of financings. Tanner’s clients have included Pfizer in its $60 billion acquisition of Pharmacia, Amgen in its $16 billion acquisition of Immunex, Rhône-Poulenc in its $1.8 billion acquisition of Rorer, followed by representing Rhône-Poulenc Rorer in its £ 1.8 billion acquisition of U.K. company Fisons, Marion Merrell Dow in its $7.1 billion acquisition by Hoechst BASF/BASF Pharma, in its £ 840 million acquisition of U.K. Boots Pharmaceuticals.

Tanner received a B.A. magna cum laude from Harvard University. Ms. Tanner is a member of the Board of Directors of Lineagen, Inc., a molecular diagnostic company, and Genticel , S.A., an immuno oncology company. She serves on the Dean’s Council of the Yale Medical School and the Yale School of Organization and Management Advisory Board. Ms. Tanner has been honored for her contributions to biotechnology with numerous awards, including the highest award of Springboard Enterprises, the Oracle, for professional accomplishment and mentoring of women entrepreneurs.

Tel: 212-461-1601

Anton Gueth began his career in the pharmaceutical business over 20 years ago at Eli Lilly and Company. His global finance and operating experience spans the U.S., Europe, the Middle East and Africa. Before joining EVOLUTION Life Science Partners, Mr. Gueth was a Managing Director of Burrill Securities. He is also the founder and Managing Partner of GUETH CONSULTING LLC, a consulting firm focusing on pharmaceutical and biotechnology clients in the areas of licensing, early stage financing and alliance management. His clients over the years have included Amgen, Baxter, Boehringer Ingelheim, Bayer among many others.

While at Lilly, Mr. Gueth held multiple positions of increasing responsibility, including Area Director Africa/Middle East and concluding as Director of Alliance Management. Mr. Gueth is a member of the board of directors of Antares Pharma. He is also on the board of the California chapter of the American Liver Foundation. Mr. Gueth received his master’s degree in public affairs from Indiana University and an M.S. in agricultural economics from Justus Liebig University in Germany.

Tel: 415-867-3863

David Parke is a Managing Director of EVOLUTION Life Science Partners.  Mr. Parke specializes in capital raise and mergers and acquisitions for life science companies. His experience delivers a strong background in capital markets with an in-depth understanding of the issues particular to biotechnology and other development stage companies. He was previously with Burrill Securities, which he joined in 2011, where he managed a number of acquisition and financing engagements for both public and private firms. His experience prior to Burrill includes Boenning & Scattergood and Investec.

Mr. Parke is a Member of the Life Science Advisory Board of IP Group North America. He is also a director of PDC Energy, a publicly-traded natural gas exploration and production company, which he joined in 2003. Mr. Parke received his MBA with Honors from The Wharton School of the University of Pennsylvania, and graduated summa cum laude and Phi Beta Kappa from Lehigh University with a B.S. in Finance.

Tel: 215-990-0016

Christa Nicholas is a Senior Advisor at EVOLUTION Life Science Partners.  Ms. Nicholas specializes in partnering, M&A, and related activities required for successful exits for life science companies. Her experience draws from over 30 years working with pharmaceutical companies in operational roles, including market planning, commercial strategy, and medical affairs. She was previously with Takeda, Novartis, Genentech and Bain Capital.

Ms. Nicholas received her AB History and Certificate of European Studies from Princeton University.

Tel: 510-423-1673

Neal Fischer is a Director at EVOLUTION Life Science Partners. Mr. Fischer focuses on valuation, licensing, strategic advisory, and capital raising. He was previously with Burrill Securities, a life science focused investment bank, which he joined in 2011. He also worked in the Life Sciences Investment Banking Group at Janney Montgomery Scott. He has also worked at the Bank of New York Mellon.

Mr. Fischer has a Masters of Finance from The Pennsylvania State University and graduated cum laude with a dual degree B.A. in International Business and East Asian Studies from Dickinson College. He has studied in China at Peking University and the Beijing Language and Culture University and speaks Mandarin Chinese.

Tel: 415-889-0479